Acadian Diagnostic Laboratories LLC

Acadian Diagnostic Laboratories LLC was paid $6.81M by Medicaid between Jan 2018 and Apr 2021, across 138 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 24% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Louisiana

Rank by total paid#10 of 66

Median peer was paid$253K

This provider vs. median27×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	288,463	$3.60M
2019	217,831	$3.17M
2020	646	$27K
2021	342	$8K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	24%	18,017	13,338	$1.65M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	5.9%	6,808	3,089	$405K
80336		2.5%	14,477	6,354	$174K
80372		2.5%	15,352	6,670	$169K
80367		2.5%	15,327	6,658	$169K
80373		2.5%	15,314	6,665	$169K
80366		2.4%	15,231	6,599	$163K
80357		2.4%	14,891	6,359	$163K
80368		2.4%	15,227	6,567	$163K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	2.3%	4,522	2,048	$159K
80346		2.3%	15,393	6,684	$157K
80361		2.2%	15,343	6,681	$148K

126 more codes

80354		2.2%	15,392	$148K
80356		2.2%	15,344	$148K
80339		2.2%	14,984	$147K
80348		2.1%	14,727	$146K
80365		2.1%	15,282	$145K
80360		2.1%	14,944	$141K
80358		2.1%	15,364	$141K
80323		2.1%	12,209	$140K
80371		2.0%	14,857	$140K
80364		2.0%	14,233	$139K
80349		2.0%	14,747	$139K
80369		2.0%	11,371	$135K
80359		2.0%	15,264	$133K
80350		1.9%	14,260	$130K
80338		1.9%	11,235	$130K
80353		1.9%	15,159	$129K
83992		1.9%	13,698	$127K
80324		1.8%	11,867	$124K
80355		1.6%	14,092	$110K
80321		1.5%	13,517	$105K
80370		<1%	3,819	$37K
80332		<1%	3,232	$30K
81403		<1%	393	$22K
81405		<1%	396	$22K
81404		<1%	394	$19K
81211		<1%	264	$18K
81201		<1%	400	$15K
81317		<1%	395	$14K
81298		<1%	394	$14K
81288		<1%	396	$14K
81295		<1%	394	$13K
80325		<1%	3,670	$11K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	123	$11K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	578	$10K
81325		<1%	211	$9K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,899	$9K
80050	General health panel	<1%	400	$9K
81259		<1%	213	$9K
81242		<1%	211	$8K
84403		<1%	1,107	$8K
82670		<1%	987	$7K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	85	$6K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,167	$6K
80061	Lipid panel	<1%	1,691	$5K
84270		<1%	988	$5K
80053	Comprehensive metabolic panel	<1%	1,801	$5K
80335		<1%	705	$5K
80347		<1%	663	$5K
82607		<1%	1,225	$5K
84144		<1%	912	$4K
80362		<1%	694	$4K
82627		<1%	872	$4K
83001		<1%	922	$4K
84146		<1%	871	$4K
83002		<1%	875	$4K
84681		<1%	853	$4K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,829	$3K
82533		<1%	877	$3K
84443	Thyroid stimulating hormone (TSH)	<1%	1,420	$3K
82746		<1%	843	$3K
84481		<1%	975	$3K
82728		<1%	1,072	$3K
83003		<1%	789	$3K
83525		<1%	900	$2K
80363		<1%	200	$2K
82172		<1%	847	$2K
84439		<1%	1,108	$2K
83735		<1%	1,112	$1K
83695		<1%	876	$1K
84153		<1%	320	$1K
82150		<1%	912	$1K
83540		<1%	784	$1K
83550		<1%	657	$1K
84550		<1%	895	$1K
82977		<1%	633	$1K
86140		<1%	1,007	$1K
84402		<1%	229	$991.91
84702		<1%	311	$915.50
84100		<1%	920	$841.77
82248		<1%	696	$718.67
86592		<1%	243	$558.89
87086	Culture, bacterial; quantitative colony count, urine	<1%	308	$535.18
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	188	$485.58
81328		<1%	58	$483.35
81230		<1%	57	$483.35
81231		<1%	60	$483.35
83937		<1%	67	$445.65
80374		<1%	125	$445.50
85027		<1%	47	$352.98
81003		<1%	277	$297.04
81025		<1%	122	$281.64
81241		<1%	58	$273.64
81001		<1%	260	$269.36
83090		<1%	244	$247.81
81479	Unlisted molecular pathology procedure	<1%	59	$195.75
80048	Basic metabolic panel (calcium, ionized)	<1%	180	$187.03
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	19	$182.39
81240		<1%	58	$181.59
80076		<1%	175	$180.10
81291		<1%	58	$150.36
81227		<1%	61	$141.71
86900		<1%	177	$124.99
85651		<1%	70	$119.74
80334		<1%	13	$115.50
87631		<1%	14	$114.10
87340		<1%	146	$90.56
81355		<1%	58	$79.03
86762		<1%	142	$78.64
87634		<1%	14	$57.28
82043		<1%	34	$42.89
86850		<1%	159	$30.51
85007		<1%	41	$27.03
86901		<1%	173	$22.21
82947		<1%	76	$16.78
82950		<1%	14	$5.84
81401		0%	57	$0.00
0032U		0%	17	$0.00
80164		0%	13	$0.00
G0103	Prostate cancer screening; prostate specific antigen test (psa)	0%	48	$0.00
81225		0%	61	$0.00
81226		0%	61	$0.00
86701		0%	17	$0.00
84479		0%	67	$0.00
84436		0%	106	$0.00
84480		0%	103	$0.00
0031U		0%	17	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILKS, TERRY (CEO/OWNER)

Same official

Other billing entities under WILKS, TERRY

Full network →

Provider	Location	Paid
Evangeline Diagnostic Center LLC	Ville Platte, LA	$2.85M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.